No Data
Erkang Pharmaceuticals: 2024 Annual Report Summary
Erkang Pharmaceuticals: Report for the first quarter of 2025
Erkang Pharmaceuticals: 2024 Annual Report
Hunan Er-kang Pharmaceutical (300267.SZ) released its performance report for 2024, with a net loss attributable to the parent company of 0.373 billion yuan, an increase of 91.16%.
Hunan Er-kang Pharmaceutical (300267.SZ) released its annual report for 2024, with the company's revenue amounting to 1.14 billion yuan...
Is Hunan Er-Kang Pharmaceutical (SZSE:300267) Weighed On By Its Debt Load?
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Hunan Er-Kang Pharmaceutical (SZSE:300267) Has Debt But No Earnings; Should You Worry?
